Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer

Stem Cells International

Volumn 2015, Issue , 2015, Pages

  Ng, Lui ^a   Wan, Timothy ^a   Chow, Ariel ^a   Iyer, Deepak ^a   Man, Johnny ^a   Chen, Guanghua ^a   Yau, Thomas Chung Cheung ^a   Lo, Oswens ^a   Foo, Chi Chung ^a   Poon, Jensen Tung Chung ^a   Poon, Ronnie Tung Ping ^a   Pang, Roberta ^a   Law, Wai Lun ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; FLUOROURACIL; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOPONTIN; OXALIPLATIN; TRANSCRIPTION FACTOR SOX2;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CELL SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 84935888942     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2015/247892     Document Type: Article

References (25)

1. M. Shike, S. J. Winawer, P. H. Greenwald, A. Bloch, M. J. Hill, and S. V. Swaroop, "Primary prevention of colorectal cancer. The WHO Collaborating Centre for the Prevention of Colorectal Cancer," Bulletin of the World Health Organization, vol. 68, no. 3, pp. 377-385, 1990.
2. T. Armaghany, J. D. Wilson, Q. Chu, and G. Mills, "Genetic alterations in colorectal cancer," Gastrointestinal Cancer Research, vol. 5, no. 1, pp. 19-27, 2012.
3. J. J. Y. Sung, J. Y. W. Lau, G. P. Young et al., "Asia Pacific consensus recommendations for colorectal cancer screening," Gut, vol. 57, no. 8, pp. 1166-1176, 2008.
4. J. S. Lin, E. M. Webber, T. L. Beil, K. A. Goddard, and E. P. Whitlock, "FecalDNA testing in screening for colorectal cancer in average-risk adults," Tech. Rep. 12-EHC022-EF, Agency for Healthcare Research and Quality (US), Rockville, Md, USA, 2012.
5. A. Bellahcene, V. Castronovo, K. U. E. Ogbureke, L. W. Fisher, and N. S. Fedarko, "Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer," Nature Reviews Cancer, vol. 8, no. 3, pp. 212-226, 2008.
6. T. E. Kruger, A. H. Miller, A. K. Godwin, and J. Wang, "Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers," Critical Reviews in Oncology/Hematology, vol. 89, no. 2, pp. 330-341, 2014.
7. W. Likui, W. Hong, Z. Shuwen, Y. Yuangang, and W. Yan, "The potential of osteopontin as a therapeutic target for human colorectal cancer," Journal ofGastrointestinal Surgery, vol. 15, no. 4, pp. 652-659, 2011.
8. L. Ng, T. M. Wan, C. S. Lam et al., "Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer," PLOS ONE, vol. 10, no. 5, Article IDe0126219, 2015.
9. M. Todaro, M. Gaggianesi, V. Catalano et al., "CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis," Cell Stem Cell, vol. 14, no. 3, pp. 342-356, 2014.
10. V. Lamour, A. Henry, J. Kroonen et al., "Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo," International Journal of Cancer, 2015.
11. L. Ng, R. Tung-Ping Poon, S. Yau et al., "Suppression of actopaxin impairs hepatocellular carcinomametastasis through modulation of cellmigration and invasion," Hepatology, vol. 58, no. 2, pp. 667-679, 2013.
12. W. Luo, S. Li, B. Peng, Y. Ye, X. Deng, and K. Yao, "Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma," PLoS ONE, vol. 8, no. 2, Article ID e56324, 2013.
13. T. Gu, R. Ohashi, R. Cui et al., "Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer," Lung Cancer, vol. 66, no. 2, pp. 176-183, 2009.
14. M. Graessmann, B. Berg, B. Fuchs, A. Klein, and A. Graessmann, "Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3," Oncogene, vol. 26, no. 20, pp. 2840-2850, 2007.
15. C. Qian, P. Li, W. Yan et al., "Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting theNF-kappaB/Bcl2 pathway," Molecular Medicine Reports, vol. 11, no. 3, pp. 1951-1955, 2015.
16. H. Kashihara, M. Shimada, N. Kurita et al., "CD133 expression is correlated with poor prognosis in colorectal cancer," Hepatogastroenterology, vol. 61, no. 134, pp. 1563-1567, 2014.
17. H. Hsu, Y. Liu, K. Tseng, B. C. Tan, S. Chen, and H. Chen, "LGR5 regulates survival through mitochondria-mediated apoptosis and by targeting the Wnt/β-catenin signaling pathway in colorectal cancer cells," Cellular Signalling, vol. 26, no. 11, pp. 2333-2342, 2014.
18. E. Dotse and Y. Bian, "Isolation of colorectal cancer stem-like cells," Cytotechnology, 2014.
19. Y.-X. Lu, L. Yuan, X.-L. Xue et al., "Regulation of colorectal carcinoma Stemness, Growth, and metastasis by an miR-200c-Sox2-negative feedback loop mechanism," Clinical Cancer Research, vol. 20, no. 10, pp. 2631-2642, 2014.
20. X. Han, X. Fang, X. Lou et al., "Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients," PLoS ONE, vol. 7, no. 8, Article ID e41335, 2012.
21. D. Yang, H. Wang, J. Zhang et al., "In vitro characterization of stem cell-like properties of drug-resistant colon cancer subline," Oncology Research, vol. 21, no. 1, pp. 51-57, 2013.
22. K. Wen, Z. Fu, X. Wu, J. Feng, W. Chen, and J. Qian, "Oct is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: effects associated with STAT3/Survivin," Cancer Letters, vol. 333, no. 1, pp. 56-65, 2013.
23. A. B. Tuck, A. F. Chambers, and A. L. Allan, "Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management," Journal of Cellular Biochemistry, vol. 102, no. 4, pp. 859-868, 2007.
24. Z. Mi, S. D. Bhattacharya, V. M. Kim, H. Guo, L. J. Talbotq, and P. C. Kuo, "Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis," Carcinogenesis, vol. 32, no. 4, pp. 477-487, 2011.
25. M. Bandopadhyay, A. Bulbule, R. Butti et al., "Osteopontin as a therapeutic target for cancer," Expert Opinion on Therapeutic Targets, vol. 18, no. 8, pp. 883-895, 2014.